Aberrant regulation of epigenetic modifiers contributes to the pathogenesis in patients with selenoprotein N‐related myopathies
Congenital myopathies are early onset, slowly progressive neuromuscular disorders of variable severity. They are genetically and phenotypically heterogeneous and caused by pathogenic variants in several genes. Multi‐minicore Disease, one of the more common congenital myopathies, is frequently caused...
Saved in:
Published in: | Human mutation Vol. 40; no. 7; pp. 962 - 974 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article Web Resource |
Language: | English |
Published: |
United States
Hindawi Limited
01-07-2019
John Wiley and Sons Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Congenital myopathies are early onset, slowly progressive neuromuscular disorders of variable severity. They are genetically and phenotypically heterogeneous and caused by pathogenic variants in several genes. Multi‐minicore Disease, one of the more common congenital myopathies, is frequently caused by recessive variants in either SELENON, encoding the endoplasmic reticulum glycoprotein selenoprotein N or
RYR1, encoding a protein involved in calcium homeostasis and excitation–contraction coupling. The mechanism by which recessive
SELENON variants cause Multiminicore disease (MmD) is unclear. Here, we extensively investigated muscle physiological, biochemical and epigenetic modifications, including DNA methylation, histone modification, and noncoding RNA expression, to understand the pathomechanism of MmD. We identified biochemical changes that are common in patients harboring recessive
RYR1 and
SELENON variants, including depletion of transcripts encoding proteins involved in skeletal muscle calcium homeostasis, increased levels of Class II histone deacetylases (HDACs) and DNA methyltransferases. CpG methylation analysis of genomic DNA of patients with
RYR1 and
SELENON variants identified >3,500 common aberrantly methylated genes, many of which are involved in calcium signaling. These results provide the proof of concept for the potential use of drugs targeting HDACs and DNA methyltransferases to treat patients with specific forms of congenital myopathies.
We investigated physiological, biochemical, and epigenetic modifications in muscles of patients with SELENON‐related congenital myopathy. We identified biochemical changes that are common in patients harboring recessive
RYR1 and
SELENON variants, including depletion of transcripts encoding proteins involved in skeletal muscle calcium homeostasis, increased levels of Class II histone deacetylases (HDACs), and DNA methyltransferases. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 scopus-id:2-s2.0-85063687545 |
ISSN: | 1059-7794 1098-1004 1098-1004 |
DOI: | 10.1002/humu.23745 |